Pfizer Ltd (PFIZER) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 500680 | NSE: PFIZER | Pharmaceuticals & Drugs | Small Cap

Pfizer Share Price

4,995.25 -7.55 -0.15%
as on 05-Dec'25 16:59

Pfizer Ltd (PFIZER) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 500680 | NSE: PFIZER | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Pfizer

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Pfizer stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
27.27
Market Cap:
22,886.7 Cr.
52-wk low:
3,742.9
52-wk high:
5,987.7

Is Pfizer Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Pfizer: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Pfizer Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 22.8%22.6%21.5%23.2%20.4%23.6%29.8%27.6%22.4%26.2%-
Value Creation
Index
0.70.70.60.70.51.11.71.01.00.9-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2,0121,9661,9692,0822,1522,2392,6112,4252,1932,2812,375
Sales YoY Gr.--2.3%0.1%5.7%3.4%4%16.6%-7.1%-9.6%4%-
Adj EPS 63.952.977.789.4106.8108133.4131119.8141.6183.5
YoY Gr.--17.3%46.9%15.1%19.5%1.1%23.5%-1.8%-8.5%18.2%-
BVPS (₹) 472.9528.7586.5658.2742.2523.1626.1701.1785.9921.8841.2
Adj Net
Profit
292242355409489494610599548648839
Cash Flow from Ops. 34532933297.8323427667356257660-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 1.4%1.2%-4.4%4%
Adj EPS 9.2%5.8%2%18.2%
BVPS7.7%4.4%13.8%17.3%
Share Price 7.1% -1% 3.1% -5.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
14.110.613.914.415.317.123.219.716.116.620.8
Op. Profit
Mgn %
21.617.825.527.326.931.832.133.429.232.534.3
Net Profit
Mgn %
14.512.318.119.722.722.123.424.72528.435.3
Debt to
Equity
00000000000
Working Cap
Days
158150162182195194169182208206255
Cash Conv.
Cycle
-1-10-40-27-4620234557211

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Pfizer Ltd.

Standalone Consolidated
TTM EPS (₹) 183.5 30
TTM Sales (₹ Cr.) 2,375 772
BVPS (₹.) 841.2 0
Reserves (₹ Cr.) 3,803 965
P/BV 5.95 0.00
PE 27.27 166.91
From the Market
52 Week Low / High (₹) 3742.90 / 5987.65
All Time Low / High (₹) 27.50 / 6452.85
Market Cap (₹ Cr.) 22,887
Equity (₹ Cr.) 45.8
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Pfizer:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Pfizer - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Pfizer

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales2,0121,9661,9692,0822,1522,2392,6112,4252,1932,281
Operating Expenses 1,5791,6161,4681,5161,5791,5261,7751,6161,5581,541
Manufacturing Costs164162131143116130138129118109
Material Costs699712678678742734876803730756
Employee Cost 277304314324365361404332348371
Other Costs 439439345370357301358352362305
Operating Profit 433350501566573712836809635740
Operating Profit Margin (%) 21.5%17.8%25.4%27.2%26.6%31.8%32.0%33.4%29.0%32.5%
Other Income 871011141671848163101181172
Interest 121211151113159
Depreciation 586366711031091151066261
Exceptional Items 1013000000338173
Profit Before Tax 4705175486606426697738247461,016
Tax 165180188231133171160200195248
Profit After Tax 305337360429509498613624551768
PAT Margin (%) 15.2%17.1%18.3%20.6%23.7%22.2%23.5%25.7%25.1%33.6%
Adjusted EPS (₹)66.773.678.793.8111.3108.8133.9136.4120.5167.8
Dividend Payout Ratio (%)23%27%25%24%297%32%22%51%29%98%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 2,1632,4192,6833,0113,3952,3932,8643,2073,5964,217
Share Capital 46464646464646464646
Reserves 2,1182,3732,6372,9663,3502,3472,8193,1623,5504,172
Minority Interest0000000000
Debt3333333333
Long Term Debt3000000000
Short Term Debt0333333333
Trade Payables338388496436427284264217166152
Others Liabilities 384452509490580573723476411470
Total Liabilities 2,8883,2613,6903,9404,4053,2523,8543,9034,1754,842

Fixed Assets

Gross Block9819831,0951,1001,2771,2791,3451,3521,3561,418
Accumulated Depreciation56116178246335414504603643695
Net Fixed Assets 925867917854942865841749713724
CWIP 31510131808
Investments 0000000000
Inventories361322297387431435449418434476
Trade Receivables142110155172172109143152188193
Cash Equivalents flag 1,0251,5231,7721,9142,2201,1151,6431,8602,0472,801
Others Assets 432423549613640726777717794641
Total Assets 2,8883,2613,6903,9404,4053,2523,8543,9034,1754,842

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 34532933298323427667356257660
PBT 4705175486606426697738247461,016
Adjustment -20-154-33-79-545576-131-89-257
Changes in Working Capital 6914910-245-52-9244-34-24657
Tax Paid -174-183-194-238-213-204-226-303-154-156
Cash Flow From Investing Activity -701-250-238351,530-469-575-3654-71
Capex 53169-6927-2-18-13-6434-28
Net Investments -833-502000-502-613-229-109-354
Others 7984-16981,5325151257129311
Cash Flow From Financing Activity -62-83-110-110-164-1,571-181-346-235-205
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 0000-0-3-11-13-11-8
Dividend Paid -50-69-92-91-103-1,519-160-297-183-160
Others -12-14-19-19-60-49-10-35-41-37
Net Cash Flow -417-3-17231,690-1,613-88-2675383

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)14.7514.714.1115.0715.8917.1923.320.5516.2119.65
ROCE (%)22.7822.6221.4923.2220.3823.6229.7827.5622.3726.21
Asset Turnover Ratio0.770.660.570.550.520.580.760.660.570.53
PAT to CFO Conversion(x)1.130.980.920.230.630.861.090.570.470.86
Working Capital Days
Receivable Days26232429292317212729
Inventory Days65615760697159626770
Payable Days1761862382512121771141099677

Pfizer Ltd Stock News

Pfizer Ltd FAQs

The current trading price of Pfizer on 05-Dec-2025 16:59 is ₹4,995.3.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Pfizer stood at ₹22,886.7.
The latest P/E ratio of Pfizer as of 04-Dec-2025 is 27.27.
The latest P/B ratio of Pfizer as of 04-Dec-2025 is 5.95.
The 52-week high of Pfizer is ₹5,987.7 and the 52-week low is ₹3,742.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Pfizer is ₹2,375 ( Cr.) .

About Pfizer Ltd

Pfizer is a Public Limited Company, incorporated under the Indian Companies Act, 1913, having its registered office in Mumbai, Maharashtra and is listed on the BSE Limited and the National Stock Exchange of India Limited

Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. The company is taking on some of the world's most difficult diseases, including cancer, arthritis, and osteoporosis.

Business area of the company

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

Awards

2001

  • OPPI Brand Excellence Award for Minipress XL.

2002

  • Express Pharma Biz Award for overall performance.
  • Rated as one of India's most socially responsive companies. Awarded by FICCI-Socio Economic Development Foundation for our Social Responsiveness.

2003

  • Voted as the 5 'Most Respected Company' in the Pharma sector (Business World).
  • Corporate Advertising Campaign won a Silver Award at the ABBY-All India Awards for Creative Excellence. Gelusil brand received a Silver Award for printing advertising.
  • Golden Peacock National Training Special Commendation for Training practices.

2004

  • Ranked 5 among all pharmaceutical companies, with respect to corporate image, field-force, and promotional programs (AC Nielsen-ORG Marg 'Corporate Image Survey').
  • Ranked 1 among all Pharma MNCs & 4 among all Pharma Companies by Business World.
  • Kewal Handa, CFO Pfizer Limited receives the ‘India CFO 2004 - Excellence in Finance in an MNC’ by International Market - Assessment Group.

2005

  • Golden Peacock Innovative Service Award for Prime MD Today (Daxid).
  • PC Quest 'Best IT Implementation Users Choice' award for OPTILEARN.
  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and #3 among all pharmaceuticals, in the Business World survey.

2006

  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and 3 among all pharmaceuticals, in the Business World survey.
  • Kewal Handa, Managing Director Pfizer, awarded the Bharat Shiromani award for his outstanding contribution in the pharmaceutical industry.

2007

  • Reader’s Digest Trusted Brand Asia - Gold Award 2007’ in the vitamin and health supplement category for Becosules.

2008

  • Frost & Sullivan Brand Strategy Leadership Award for Becosules in the Indian Dietary Supplement Market.
  • Pfizer India was recently conferred the ‘Innovative Training Practices’ Award for promoting effective and optimum utilization of human resource through education and training by the Indian Society for Training and Development (ISTD).

2009

  • Pfizer Limited (India) conferred the Multinational Pharmaceutical Company of the Year by Frost & Sullivan.

2010

  • Pfizer Limited awarded the Most Admired Pharmaceutical Company of the Year by Pharma Leaders Magazine.
  • Kewal Handa, Country Manager - Pfizer Limited recognized as Pharma Professional of the Year by Pharma Leaders Magazine.
  • Pfizer wins the Community Engagement Award at the Asia Responsible Entrepreneurship Awards 2010 in India.

2011

  • Pfizer India has been recognized as one of The Best Companies to Work For by Business Today magazine.

2012

  • J.D. Power and Associates has honored the MS LifeLines call center with certification for an outstanding customer service experience. This is the first time J.D. Power has recognized a pharmaceutical call center. Click Here.

2013

  • GBCHealth Business Leadership Award - in recognition for the Global Health Fellows program. This award is given annually to a company or business leader with a deep and long-term commitment to global health that extends beyond the business objective of the company itself. Caroline Roan will be accepting the award on behalf of Pfizer.
  • Business Action on Health Award in Application of Core Competence for Global Health Fellows Program (commendation). Oonagh Puglisi will be accepting the award for the GHF program.
  • Business Action on Health Award in Partnership/Collective Action for Advancing Cancer & Tobacco Control in China Program. Danlong Feng, Corporate Affairs Director, Pfe China, will be accepting the award.
  • QUESTAR Award - The International Awards Festival for Excellence in Video Communications Pfizer was awarded the Grand -- best of category -- in Annual Reports in the 2013 Questar Awards.
  • Telly Award - For over a quarter century, the Telly statuette has been a symbol of creative excellence. Pfizer was awarded - Bronze at the 2013 Telly's for online videos.

Milestones:

  • 1849: Charles Pfizer & Company established. 1' product for treatment of intestinal worms is a success.
  • 1880: Pfizer manufactures Citric Acid. Rapid growth on the back of aerated drinks demand.
  • 1882: Alexander Fleming discovers penicillin.
  • 1944: Pfizer finds a way to mass-produce Penicillin.
  • 1950: Terramycin, the 1st pharmaceutical sold in the US under the Pfizer label.
  • 1950: India operation launched, with HQ in Mumbai.
  • 1966: Pfizer listed on the Bombay Stock Exchange.
  • 1989: Dolonex (Feldene) launched in India.
  • 1993: Amlogard (Norvasc) launched in India.
  • 1996: Launch of MinipressXL, an anti hypertensive drug.
  • 1998: Launch of Viagra, for erectile dysfunction.
  • 1999: Pfizer listed on the National Stock Exchange.
  • 2000: Launch of Magna& a unique hospital antibiotic.
  • 2002: Futuristic tablet manufacturing Goa plant commissioned in a record 13 months.
  • 2003 Completes merger with Parke-Davis (India) Ltd.
  • 2005: Announces merger with Pharmacia Healthcare ltd.
  • 2006: Launch of LYRICA (pregaballn for treatment of neuropathic pain)
  • 2008: Launch of Champix - a non-nicotine smoking cessation prescription drug.
  • 2010: Launch of Prevenar 13, vaccine for prevention of pneumococcal disease and included later in India’s Universal Immunization Programe.
  • 2015: Completed merger with Wyeth Limited.
  • 2016: Launched Xeljanz-the first oral Janus Kinase (JAK) inhibitor.
  • 2017: Acquires 2 breakthrough brands- Meronem, Neksium.
  • 2019: Reorganizes into 3 distinct business units: Pfizer Biopharma Group, UpJohn and Consumer Healthcare. New purpose and values unveiled.
  • 2019: Launches novel anti-bacterial Zavicefta in India.
  • 2020: Launch of Zinforo, a noval cephalosporin indicated for treatment of adult patients with community- acquired Pneumonia.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×